Register Login

Mineralys Therapeutics Inc (MLYS)

(10% Negative) MINERALYS THERAPEUTICS, INC. (MLYS) Announces Delay in Event Development Timeline Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 6, 2026, 1:10 p.m.

    📋 MINERALYS THERAPEUTICS, INC. (MLYS) - Clinical Trial Update

    Filing Date: 2026-01-06

    Accepted: 2026-01-06 08:05:47

    Event Type: Clinical Trial Update

    Event Details:

    Mineralys Therapeutics Inc (MLYS) Announces Clinical Trial Update Mineralys Therapeutics Inc (MLYS) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Event, data
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: LifeSci Partners Corporate Access Event

    🔬 Clinical Development Pipeline (MINERALYS THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    lorundrostat Dose 2 DRUG Phase PHASE3 Hypertension ClinicalTrials.gov
    lorundrostat Dose 1 DRUG Phase PHASE3 Hypertension ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Hypertension ClinicalTrials.gov
    Lorundrostat DRUG Phase PHASE2 Obstructive Sleep Apnea ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Mineralys Therapeutics Inc
    • CIK: 0001933414
    • Ticker Symbol: MLYS
    • Period End Date: 2026-01-06
    • Document Type: 8-K

Search

News categories